Please assess the completion status of the following clinical trial:

Trial Title: TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive subjects with pulmonary M. tuberculosis infection, willing to start anti-TB therapy~* Positive for acid-fast bacilli on direct smear exam of sputum specimen~* Must consent to HIV testing~* Must agree to hospital admission~Exclusion Criteria:~* History or presence of hepatic or GI disease that may interfere with the absorption of TMC207, isoniazid or rifampin~* Subjects who received previous anti-mycobacterial drugs for the treatment of a mycobacteria infection and subjects who have received more than 2 weeks of treatment with a fluoroquinolone~* Subjects who have received antiretroviral therapy and/or oral or I.V. anti-fungal medication w/in the last 90 days~* Subjects with sputum cultures of M. tuberculosis resistant to rifampin~* Impaired hepatic function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).